Studies in NSCLC showed that patients with CD8 lymphocytes lacking PD-1 were associated with a more favourable clinical outcome than those harbouring CD8 lymphocytes expressing PD-1 [14,39]. Here, CD8A is linked to non-small cell lung carcinoma.